PrecisePK is Made to Benefit Your Institution
Learn more about how PrecisePK can improve your patient care while providing a return on investment for your organization
PrecisePK Helps You
1
Maximize clinical efficiency by saving time and reducing workload for complex calculations.
With just a few clicks, clinical pharmacists can receive practical and individualized dosage recommendations.
2
Save lives by better reaching therapeutic targets faster and reducing toxicity incidences.
By tailoring dosage recommendations to individual patients and using our Prediction features, therapeutic targets can be reached more efficiently and safely.
3
Save on costs by preventing ADEs, avoiding malpractice claims and reducing extended hospital stays.
Therapeutic Drug Monitoring helps your institution cut back on a multitude of indirect costs.
4
Fully comply with industry standard guidelines, such as the 2020 ASHP/IDSA Vancomycin Guidelines.
Per the latest guidelines, AUC-based monitoring is preferred over trough-based monitoring as the most accurate and optimal way to manage vancomycin dosing. PrecisePK uses Bayesian principles to accurately and easily calculate AUC.
Maximize Your Return on Investment with PrecisePK
$60,305
savings per year for using AUC24 Vancomycin Bayesian-Based Dosing
Paul E Sabourenkov, MBioinf, Robert C McLeay, PhD, 1599. AUC24 Vancomycin Bayesian-Based Dosing: Increasing Therapeutic Target Attainment with DecreasedTDM Cost, Open Forum Infectious Diseases, Volume 6,Issue Supplement_2, October 2019, Page S583, https://doi.org/10.1093/ofid/ofz360.1463
10 days
reduced length of hospital stay per patient using TDM guidance
Paul E Sabourenkov, MBioinf, Robert C McLeay, PhD, 1599. AUC24 Vancomycin Bayesian-Based Dosing:Increasing Therapeutic Target Attainment with DecreasedTDM Cost, Open Forum Infectious Diseases, Volume 6,Issue Supplement_2, October 2019, Page S583, https://doi.org/10.1093/ofid/ofz360.1463
$376,500
savings of malpractice claims due to preventable inpatient ADEs
Rothschild JM, Federico FA, Gandhi TK, Kaushal R,Williams DH, Bates DW. Analysis of Medication-Related Malpractice Claims: Causes, Preventability, and Costs. Arch Intern Med. 2002;162(21):2414–2420.doi:10.1001/archinte.162.21.2414
52:1
in benefits-to-cost from using a TDM software (aminoglycosides)
Schumacher GE, Barr JT. Economic and outcome issues for therapeutic drug monitoring in medicine. 1998.
10.5%
van Lent-Evers NA et al. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. 1999;21(1):63‐73.
reduction in nephrotoxicity incidences from using a TDM software (aminoglycosides)